Topical pharmaceutical compositions for treatment of tissue damage
WO2018150257A1
Treatment with highly purified eicosapentaenoic acid as free fatty acid improves inflammation, affects colonic differentiation markers and microbiota in patients with ulcerative colitis
CN108778284A
High-purity free fatty eicosapentaenoic acid reduces patients of ulcerative colitis excrement calprotectin levels and prevents clinical recurrence
WO2013012662A2
Pharmaceutical compositions for rectal administration
GB0428384D0
Eicosapentaenoic acid
CA2496864A1
A pharmaceutical composition
AU2003203991B2
Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
GB0130757D0
Compositions for treatment of detrusor instability
AU2089302A
Solid polyunsaturated fatty acid compositions
GB0123157D0
Solid polyunstaturated fatty acid compositions
AU3891801A
Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
GB0102855D0
A treatment of achalasia or hypertensive lower oesophageal sphincter
GB0102854D0
A treatment of gastro-oesophageal reflux disease
GB0102856D0
A treatment of oesophageal spasm nut cracker oesophagus non-specific motility disorder and other oesophageal body dysmotility syndromes
GB0030639D0
Use of a nitric oxide synthase inhibitor in the treatment of urinary incontinence
GB0030638D0
Use of smooth muscle relaxants in the treatment or prophylaxis of urinary retention
